UBE2C Is a Potential Biomarker of Intestinal-Type Gastric Cancer With Chromosomal Instability

Jun Zhang(Qingdao University), Yingyan Yu(Fujian Medical University), Zhenggang Zhu(Wuhan Center for Disease Control and Prevention), Jiejun Wang(Shanghai Changzheng Hospital), Yihong Sun(South China Agricultural University), Yinan Chen(Henan University), Hui Cao(Huainan Normal University), Lei Liu(Affiliated Hospital of Jining Medical University), Xiaoyu Chen(Anhui Medical University), Xinyu Liu(Loudi Central Hospital), Xiaoyan Zhou(Fudan University Shanghai Cancer Center), Zhen Xiang(Fudan University Shanghai Cancer Center), Yuan Ji(Sun Yat-sen University), Jun Ji(Shanghai Jiao Tong University), Guanzhen Yu(Second Military Medical University), Jing‐Yuan Fang(Shanghai Institute of Hematology), Yuhai Bian(Shanghai Jiao Tong University), Lei Guo(Shanghai Jiao Tong University)
Frontiers in Pharmacology
August 2, 2018
10.3389/fphar.2018.00847
Cited by 76

Related Papers

Comprehensive review of targeted therapy for colorectal cancer
|Signal Transduction and Targeted Therapy|2020|1.7k
The Chinese Society of Clinical Oncology (CSCO): Clinical guidelines for the diagnosis and treatment of gastric cancer, 2021
|Cancer Communications|2021|657
m6A-dependent glycolysis enhances colorectal cancer progression
|Molecular Cancer|2020|465
Perioperative or postoperative adjuvant oxaliplatin with S-1 versus adjuvant oxaliplatin with capecitabine in patients with locally advanced gastric or gastro-oesophageal junction adenocarcinoma undergoing D2 gastrectomy (RESOLVE): an open-label, superiority and non-inferiority, phase 3 randomised controlled trial
|The Lancet Oncology|2021|436
LncRNA GLCC1 promotes colorectal carcinogenesis and glucose metabolism by stabilizing c-Myc
|Nature Communications|2019|434